Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452111 · ClinicalTrials.gov registry record · Phase 2
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
A Phase 2 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT03452111: Completed Phase 2 study, sponsored by Premier Research.
NCT03452111 is a Phase 2 study that has completed, run by Premier Research. The registered enrollment target is 420 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452111, a Phase 2 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
The long term objective is to develop a gel to be used as a male contraceptive.
Interventions
- DRUG Nestorone + Testosterone Combination Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 2 |
What the finished NCT03452111 record still lists
NCT03452111 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (216% higher).
The record links to 0 conditions, and to 1 intervention - of which Nestorone + Testosterone Combination Gel is the first listed.
NCT03452111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03452111 about?
NCT03452111 is a clinical study titled "Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception". The long term objective is to develop a gel to be used as a male contraceptive.
What is the current status of trial NCT03452111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2018-10-25. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT03452111?
The interventions under investigation include: Nestorone + Testosterone Combination Gel (DRUG).
Who is sponsoring clinical trial NCT03452111?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03452111's enrollment target sits among peer trials
420 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI